Esperion Therapeutics ESPR Deferred Tax Assets, Gross
Deferred Tax Assets, Gross at other companies
Other financials
Where this comes from
Reported directly by Esperion Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsGross.
The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Esperion Therapeutics's deferred tax assets, gross.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Esperion Therapeutics's deferred tax assets, gross?
- Esperion Therapeutics (ESPR) reported deferred tax assets, gross of $417.85M in Q4 2025.
- How has Esperion Therapeutics's deferred tax assets, gross changed year-over-year?
- Esperion Therapeutics's deferred tax assets, gross increased by 0.8% year-over-year, from $414.61M to $417.85M.
- What is the long-term trend for Esperion Therapeutics's deferred tax assets, gross?
- Over 5 years (2020 to 2025), Esperion Therapeutics's deferred tax assets, gross has grown at a 12.9% compound annual growth rate (CAGR), from $227.8M to $417.85M.